ClinicalTrials.gg
RecruitingNCT07508033MSC-EXO vs PRFUpdated Apr 2, 2026

Evaluation of Stem Cell Exosomes Versus Platelet-Rich Fibrin in Tooth Extraction Socket Healing

A Phase 1/2 interventional study of MSC-Derived Exosomes and Platelet-rich fibrin (PRF) in Alveolar Bone Loss, Tooth Extraction and Bone Regeneration, sponsored by Al Salam University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Al Salam University · Phase 1/2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Alveolar Bone Loss with a site in Egypt — 22 open to participants now, 27 under way, none of them phase 3. Alveolar Bone Loss · Egypt.

Planned enrollment
8th of 74
40 · median 20
Started
2026
with 8 others
Phase 1/2
Only one
of the 75
Primary completion
2026-07
later than 14 of 26 live
Registered
62nd of 75
by date

Among the 75 studies in Alveolar Bone Loss with a site in Egypt, this one is the 8th largest by planned enrollment of the 74 interventional ones that give a count, is one of 9 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 14 of the 26 other live ones, and was the 62nd registered.

Alveolar Bone Loss

320 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.

Browse Alveolar Bone Loss studies →

Open to participants now

22 of the 75 studies in Alveolar Bone Loss with a site in Egypt are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.

This study: 20 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Alveolar Bone Loss with a site in Egypt, or all of them as a file.
02

Study summary

This study evaluates two different treatments used to help the jawbone heal after a tooth is removed. When a tooth is extracted, the surrounding bone often shrinks, which can make it difficult to place dental implants later. Currently, doctors often use Platelet-Rich Fibrin (PRF), which is made from the patient's own blood, to help the area heal.

This research compares PRF to a newer treatment using "exosomes" derived from stem cells. Exosomes are tiny particles that carry signals to tell the body to repair tissue and grow new bone. The goal of this study is to see if these exosomes work better than PRF at keeping the bone strong and thick after an extraction. Researchers will use specialized X-rays (CBCT) to measure the bone three months after the procedure to see which treatment provided better results.

Read the detailed description

This is a randomized, single-blind, controlled clinical trial designed to compare the regenerative potential of Mesenchymal Stem Cell (MSC)-derived exosomes versus Autologous Platelet-Rich Fibrin (PRF) in alveolar ridge preservation.

A total of 40 patients requiring a single non-infected tooth extraction in the aesthetic zone or premolar area are enrolled and randomized into two equal groups (n=20).

Group A (Intervention): Following atraumatic extraction, MSC-derived exosomes are applied to the extraction socket.

Group B (Control): Following atraumatic extraction, autologous PRF (prepared via centrifugation) is placed in the socket.

The primary outcome measure is the change in alveolar bone density (measured in Hounsfield Units) and ridge dimensions (width and height) using Cone Beam Computed Tomography (CBCT) at baseline and 3 months post-operatively. Secondary outcomes include the assessment of soft tissue healing using the Landry Index, and patient-reported outcomes including postoperative pain (Visual Analog Scale) and swelling. The study aims to determine if the cell-free approach of exosome therapy provides a more standardized and effective alternative to traditional PRF for ridge preservation.

03

Conditions studied

  • Alveolar Bone Loss
  • Tooth Extraction
  • Bone Regeneration

Browse trials for

Keywords

  • MSC-derived Exosomes
  • Platelet-Rich Fibrin (PRF)
  • Alveolar Ridge Preservation
  • Socket Grafting
  • Cone-Beam Computed Tomography (CBCT)
  • Stem Cell Secretome
  • Bone Density
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 20 and 45 years.
  • Patients requiring a single tooth extraction of a non-infected tooth in the aesthetic zone (incisors, canines) or premolar area.
  • Presence of adjacent teeth to the extraction site.
  • Adequate oral hygiene (Plaque Index \< 20%).
  • Patients willing and able to comply with the follow-up schedule and 3-month CBCT scan.
  • Signed provided by the participant.

Exclusion criteria

Exclusion Criteria:

  • Patients with systemic diseases that contraindicate oral surgery or interfere with bone healing (e.g., uncontrolled diabetes, osteoporosis, hyperparathyroidism).
  • History of head and neck radiation therapy or bisphosphonate medication use.
  • Active infection or acute abscess at the extraction site.
  • Heavy smokers (more than 10 cigarettes per day).
  • Pregnant or lactating women.
  • Patients with poor oral hygiene or active periodontal disease in the rest of the mouth.
  • Use of any medications known to affect bone metabolism (e.g., long-term ).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Experimental Group (MSC-Exosomes)

    Patients in this group will receive Mesenchymal Stem Cell (MSC)-derived exosomes placed into the extraction socket immediately following tooth removal.

    Biological: MSC-Derived Exosomes

  • Active comparator
    PRF Group

    Patients in this group will receive autologous Platelet-Rich Fibrin (PRF) placed into the extraction socket immediately following tooth removal.

    Biological: Platelet-rich fibrin (PRF)

Interventions

  • BiologicalMSC-Derived Exosomes

    A cell-free regenerative therapy consisting of purified exosomes derived from mesenchymal stem cells, applied to promote bone healing and reduce ridge resorption.

  • BiologicalP-prfStudies of P-prfP-prf pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A second-generation platelet concentrate prepared by centrifuging the patient's own blood at the time of surgery to create a fibrin clot rich in growth factors.

06

What researchers measure

Primary outcomes

  1. Change in Alveolar Bone Density (Hounsfield Units)

    Bone density will be measured using Cone Beam Computed Tomography (CBCT). The mean Hounsfield Units (HU) will be calculated in the center of the extraction socket to evaluate the quality of new bone formation.

    Time frame: Baseline (Day of surgery) and 3 months post-operatively.

Secondary outcomes

  1. Alveolar Ridge Dimensional Changes (Height and Width)

    The horizontal width and vertical height of the alveolar ridge will be measured in millimeters (mm) using standardized cross-sectional CBCT images to assess the amount of bone resorption or preservation.

    Time frame: Baseline (Day of surgery) and 3 months post-operatively.

  2. Soft Tissue Healing Score (Landry Index)

    Clinical assessment of the surgical site using the Landry, Turnbull, and Heasman Index. The scale ranges from 1 (very poor) to 5 (excellent) based on tissue color, response to palpation, and presence of granulation tissue.

    Time frame: 7 days and 14 days post-operatively.

  3. Patient-Reported Postoperative Pain (VAS Score)

    Pain levels will be self-reported by patients using a Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: Daily for the first 7 days post-operatively.

07

Study locations

1 of 1 sites recruiting
  • Department of Oral & Maxillofacial Surgery, Al Salam University
    Tanta, Gharbia Governorate, Egypt
    Recruiting
    • Omaima M Sakr, BDS, MSc, PhD · Contact+201001051538
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared to protect the intellectual property of the research prior to official publication. Furthermore, the informed consent provided by the participants did not include a provision for the public sharing of raw individual data, ensuring the maintenance of patient confidentiality and privacy according to institutional ethics committee guidelines.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jul 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 2, 2026
StartActual
Jan 15, 2026
Primary completionEst.
Jul 15, 2026
CompletionEst.
Aug 1, 2026
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07508033
Lead sponsor
Al Salam University
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Jan 15, 2026
Primary completion
Jul 15, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Apr 2, 2026

Study contacts

Omaima M Sakr, BDS, MSc, PhD
Contact
drsakr2009@hotmail.com
+201001051538
Omaima M Sakr, BDS, MSc, PhD
principal investigator · Al Salam University, Faculty of Oral & Dental Medicine, Egypt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion